argenx SE commenced a tender offer for Forte Biosciences on Tuesday morning, targeting the clinical-stage dermatology developer without disclosing the per-share price in its initial filing. The transaction extends argenx's $18.7 billion market capitalization into rare inflammatory skin disorders, a vertical the company has avoided until now. Forte trades on Nasdaq under FBRX with a pre-announcement market cap near $47 million, implying a premium likely in the 60-80% range based on typical biotech tender structures.
Forte's sole clinical asset is FB-102, an anti-IL-36 receptor monoclonal antibody in mid-stage trials for pustular psoriasis and hidradenitis suppurativa. The IL-36 pathway represents validated biology after Boehringer Ingelheim's spesolimab gained FDA approval in generalized pustular psoriasis in September 2022, establishing proof-of-concept for the target. Forte reported Phase 2a data in December 2023 showing 78% of patients achieved clear or almost-clear skin at Week 16 in a 32-patient study. The company has $22 million in cash as of its most recent quarterly filing, enough to reach interim Phase 2b data but insufficient for pivotal trials without additional capital.
The acquisition fills a deliberate gap in argenx's portfolio after the company secured three FDA approvals in 18 months: Vyvgart for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and most recently pemphigus vulgaris in December 2024. Each indication targets FcRn receptor biology, a mechanism orthogonal to IL-36. argenx generated $1.87 billion in Vyvgart revenue during 2024, ahead of Street consensus by 12%, and management signaled on its February earnings call that BD capital deployment would prioritize late-stage dermatology assets with validated targets. The Forte tender satisfies the target criterion but stretches the late-stage preference, suggesting argenx sees faster regulatory pathways in pustular psoriasis than the market currently prices.
Dermatology M&A has compressed meaningfully since 2022. UCB paid $1.3 billion for Zogenix's anti-IL-36 program in March 2022 before data readouts, while Eli Lilly acquired Dice Therapeutics for $2.4 billion in December 2022 to gain an oral IL-17 inhibitor. Both deals occurred at 8-12x estimated peak sales multiples. Forte's valuation will likely settle in the $200-280 million range if argenx applies a 4-6x multiple to risk-adjusted peak sales estimates near $400 million for FB-102 in pustular psoriasis and hidradenitis combined. The discount reflects clinical risk and Forte's earlier stage relative to prior comps. The tender structure avoids drawn-out negotiations and removes the friction of Forte's $47 million float, which has averaged under 180,000 shares daily volume since November.
Allocators should monitor argenx's inflammatory skin strategy beyond Forte. The company has partnerships with Zai Lab in China and an active EU filing for Vyvgart in myasthenia gravis, but dermatology represents a $31 billion global market where IL-36 and FcRn pathways do not overlap. If argenx closes Forte and accelerates FB-102 into pivotal trials by late 2025, the company will need commercial infrastructure separate from its neurology franchise. Separately, Forte shareholders face a tender decision within 20 business days of the offer's formal commencement, likely mid-to-late June 2025 based on standard SEC timelines. Institutional holders with 41% of the float will determine whether argenx needs to sweeten terms or proceeds with a back-end squeeze-out merger at the same price.
The tender codifies argenx's shift from single-mechanism developer to multi-franchise immunology consolidator. The company exits 2024 with $2.1 billion in cash and no debt, sufficient to fund Forte and sustain Vyvgart's launch curve without equity dilution through 2027.